Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radical prostatectomy for prostate cancer within last 2 months.~* Post-operative Kattan nomogram predicts \>25% risk of PSA relapse by 5 years.~* 6-week post-operative serum PSA\<0.2ng/mL.~* Low levels of circulating prostate cancer cells in the blood, detected by PCR amplification of PSA mRNA 6 weeks post-prostatectomy.~Exclusion Criteria:~* Pre-operative serum PSA level \>20ng/ml.~* Clinical evidence of metastases by 6-week post-operative visit.~* Prior treatment with either ADT or bisphosphonate therapy.~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks) or planned dental or jaw surgery (e.g.extraction, implants)~Other protocol defined inclusion / exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): None
- Docetaxel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).